Related Experiment Video
Updated: May 9, 2026

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
Published on: February 8, 2019
[Hepatitis C virus-related cryoglobulinemic vasculitis with renal involvement: current possibilities of treatment]
Insights
This study examines kidney complications from chronic hepatitis C virus (HCV) infection, focusing on cryoglobulinemic glomerulonephritis. New treatments combine antiviral and biological therapies to target B-lymphocyte proliferation and achieve remission.
Area of Science:
- Nephrology
- Virology
- Immunology
Background:
- Chronic hepatitis C virus (HCV) infection can lead to significant renal complications.
- Cryoglobulinemic glomerulonephritis is a key manifestation of HCV-related kidney disease.
Discussion:
- The paper details clinical and morphological features of HCV-related cryoglobulinemic glomerulonephritis.
- Diagnostic and prognostic criteria are discussed.
- New therapeutic strategies are explored for severe cases.
Key Insights:
- Combination therapy with antiviral agents (pegylated interferon-alpha/ribavirin) and biological agents (anti-CD monoclonal antibodies like rituximab) shows promise.
- Treatment aims for clinical, virological, and immunological remission.
- Molecular-level response involves eliminating B lymphocyte proliferation.
Outlook:
- Further research into optimizing combination therapies for HCV-related kidney disease is warranted.
- Understanding B-lymphocyte dynamics is crucial for effective treatment strategies.
Abstract:
The paper considers the specific features of renal involvement developing in chronic infection caused by hepatitis C virus (HCV) and the current possibilities of treatment. It details the clinical and morphological manifestations of HCV-related cryoglobulinemic glomerulonephritis, and criteria for its diagnosis and prognosis. The author discuss new approaches to treating (severe cryoglobulinemic vasculitis with renal involvement in particular)--antiviral therapy (pegylated interferon-alpha/ribavirin) in combination with biological agents (anti-CD monoclonal antibodies, such as rituximab) to achieve clinical, virological, immunological remissions and a response at a molecular level--to eliminate oligo- and monoclonal B lymphocyte proliferation.
Related Concept Videos
Hepatitis
Nephrotic Syndrome II : Assessment and Medical Management
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Nephrotic Syndrome III : Nursing Management
Nephrotic Syndrome I : Introduction
Acute Pyelonephritis II: Diagnostic Studies and Management
